245 related articles for article (PubMed ID: 28114959)
1. High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study.
Yoon JH; Kim HJ; Kwak DH; Park SS; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS
J Hematol Oncol; 2017 Jan; 10(1):30. PubMed ID: 28114959
[TBL] [Abstract][Full Text] [Related]
2. Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195.
Jurcic JG; Caron PC; Miller WH; Yao TJ; Maslak P; Finn RD; Larson SM; Warrell RP; Scheinberg DA
Leukemia; 1995 Feb; 9(2):244-8. PubMed ID: 7869759
[TBL] [Abstract][Full Text] [Related]
3. Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia.
Santamaría C; Chillón MC; Fernández C; Martín-Jiménez P; Balanzategui A; García Sanz R; San Miguel JF; González MG
Haematologica; 2007 Mar; 92(3):315-22. PubMed ID: 17339180
[TBL] [Abstract][Full Text] [Related]
4. Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines.
Lengfelder E; Görlich D; Nowak D; Spiekermann K; Haferlach C; Krug U; Kreuzer KA; Braess J; Schliemann C; Lindemann HW; Horst HA; Schiel X; Flasshove M; Hecht A; Schnittger S; Schneider S; Wörmann B; Hofmann WK; Berdel WE; Bormann E; Sauerland C; Büchner T; Hiddemann W;
Eur J Haematol; 2018 Feb; 100(2):154-162. PubMed ID: 29114972
[TBL] [Abstract][Full Text] [Related]
5. Prognostic importance of expression of the Wilms' tumor 1 gene in newly diagnosed acute promyelocytic leukemia.
Hecht A; Nolte F; Nowak D; Nowak V; Reinwald M; Hanfstein B; Faldum A; Büchner T; Spiekermann K; Sauerland C; Weiss C; Hofmann WK; Lengfelder E
Leuk Lymphoma; 2015; 56(8):2289-95. PubMed ID: 25426668
[TBL] [Abstract][Full Text] [Related]
6. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.
Lucena-Araujo AR; Kim HT; Jacomo RH; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Chauffaille Mde L; Chiattone CS; Lima AS; Ruiz-Argüelles G; Undurraga MS; Martinez L; Kwaan HC; Gallagher R; Niemeyer CM; Schrier SL; Tallman MS; Grimwade D; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Sanz MA; Rego EM
Ann Hematol; 2014 Dec; 93(12):2001-10. PubMed ID: 24981688
[TBL] [Abstract][Full Text] [Related]
7. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.
Grimwade D; Jovanovic JV; Hills RK; Nugent EA; Patel Y; Flora R; Diverio D; Jones K; Aslett H; Batson E; Rennie K; Angell R; Clark RE; Solomon E; Lo-Coco F; Wheatley K; Burnett AK
J Clin Oncol; 2009 Aug; 27(22):3650-8. PubMed ID: 19506161
[TBL] [Abstract][Full Text] [Related]
8. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial.
Diverio D; Rossi V; Avvisati G; De Santis S; Pistilli A; Pane F; Saglio G; Martinelli G; Petti MC; Santoro A; Pelicci PG; Mandelli F; Biondi A; Lo Coco F
Blood; 1998 Aug; 92(3):784-9. PubMed ID: 9680345
[TBL] [Abstract][Full Text] [Related]
9. [Clinical significance of quantitation of WT1 gene expression for minimal residual disease monitoring of acute myelogenous leukemia].
Kim HR; Shin JH; Lee JN; Lee EY
Korean J Lab Med; 2007 Oct; 27(5):305-12. PubMed ID: 18094593
[TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.
Testa U; Lo-Coco F
Ann Hematol; 2016 Apr; 95(5):673-80. PubMed ID: 26920716
[TBL] [Abstract][Full Text] [Related]
12. The influence of Wilms' tumor 1 gene expression level on prognosis and risk stratification of acute promyelocytic leukemia patients.
Mitrovic M; Kostic T; Virijevic M; Karan-Djurasevic T; Suvajdzic Vukovic N; Pavlovic S; Tosic N
Int J Lab Hematol; 2020 Feb; 42(1):82-87. PubMed ID: 31830382
[TBL] [Abstract][Full Text] [Related]
13. Absolute quantification of the pretreatment PML-RARA transcript defines the relapse risk in acute promyelocytic leukemia.
Albano F; Zagaria A; Anelli L; Coccaro N; Tota G; Brunetti C; Minervini CF; Impera L; Minervini A; Cellamare A; Orsini P; Cumbo C; Casieri P; Specchia G
Oncotarget; 2015 May; 6(15):13269-77. PubMed ID: 25944686
[TBL] [Abstract][Full Text] [Related]
14. Quantification of PML/RARa transcript after induction predicts outcome in children with acute promyelocytic leukemia.
Zhang L; Cao Z; Zou Y; Ruan M; Li Q; Wang J; Zhu X
Int J Hematol; 2012 May; 95(5):500-8. PubMed ID: 22407853
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of combined WT1 and multiparameter flow cytometry assessment for measurable residual disease after induction in non-APL acute myeloid leukemia.
Ding Y; Liu Z; Wang H; Xiong S; Zhai Z
Scand J Clin Lab Invest; 2023 Sep; 83(5):340-347. PubMed ID: 37355341
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis and follow-up of acute promyelocytic leukemia by detection of PML-RAR alpha gene rearrangement.
Gau JP; Young JH; Lin TH; Yang YS
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Mar; 63(3):175-81. PubMed ID: 10746412
[TBL] [Abstract][Full Text] [Related]
17. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia.
Jurcic JG; DeBlasio T; Dumont L; Yao TJ; Scheinberg DA
Clin Cancer Res; 2000 Feb; 6(2):372-80. PubMed ID: 10690513
[TBL] [Abstract][Full Text] [Related]
18. Expression of PML-RARα is up-regulated during ATRA and arsenics combined induction without influence on long-term prognosis of acute promyelocytic leukemia.
Zhu HH; Qin YZ; Lai YY; Shi HX; Liu YR; Jiang B; Huang XJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):872-8. PubMed ID: 23998577
[TBL] [Abstract][Full Text] [Related]
19. [Detection of PML/RARa transcripts in acute promyelocytic leukemia by real-time quantitative reverse transcription polymerase chain reaction].
Lang L; Li HM; Liu H; Wang YM; Zhang XM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):714-9. PubMed ID: 17708789
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]